The Daily Buyout
~$1.5BreportedStrategic acquisitionHealthcare & Life SciencesCompleted

Repligen completes acquisition of BioLife Solutions

Repligen Corporation has closed its previously announced acquisition of Nasdaq-listed BioLife Solutions, a developer of cell processing tools and biopreservation media for the cell and gene therapy market. BioLife's CryoStor-led portfolio supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials, adding what Repligen calls a high-margin consumables business with recurring revenue to its bioprocessing lineup.

Why it matters: The deal pushes Repligen deeper into cell and gene therapy workflows, a growth pocket of life sciences tools where embedded consumables command durable revenue.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

Following healthcare M&A?

The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.

Free · Unsubscribe anytime

See what you get →